Introduction
Phillip Tuso, MD's, commentary (page 61) excellently describes the difficult challenge of caring for people in Ethiopia with chronic kidney disease. Dr Tuso raises a very important question: How much should a developing country invest in caring for the end-stage disease state versus extensive revamping of primary care to enhance preventive interventions? On the basis of 20 years of experience as a World Health Organization (WHO) consultant, I would like to discuss how WHO addresses this important question.
World Health Organization's Approach -Comprehensive and Balanced Recommendations
Dr Tuso appropriately points out that, according to WHO, comprehensive and integrated action is the means to prevent and control chronic disease.
1 Dr Tuso also notes that, regardless of the economic limitations in lowand middle-income countries, ongoing dialysis or kidney transplantation is mandatory for the survival of patients with end-stage kidney disease. He also cites the White et al recommendation to develop locally appropriate transplant programs, effective use of nongovernmental sources of funding, service planning, cost containment, use of generic drugs, and local manufacture of dialysis consumables. Also some low-and middle-income countries must rely on education, the development of good public policy, and a supportive international environment. "Prevention of end-stage kidney disease, ideally as part of an integrated approach to chronic vascular diseases, must also be a key objective." 2 These kinds of comprehensive and balanced recommendations by WHO also extend to other chronic diseases such as hypertension 3 and diabetes 4 and are consistent with my experiences as a WHO consultant. I have had the privilege of participating in several WHO evidence-based medicine (EBM) initiatives in developing countries, primarily helping Ministries of Health (MOH) in Asia, Africa, Europe, and Latin America implement improved health resource planning and management.
World Health OrganizationIntegrated Healthcare Technology Package
Today, as a United Nations organization, WHO is strategically driven by the 2015 Millennium Development Goals (MDG). 5 For example, the MDG to "scale up HIV/AIDS treatment" requires sustained country support for expanded training, and helping to strengthen physical resources such as laboratories and testing equipment. However, linking the reality "in the field" with these priorities is a huge challenge in WHO's 193 member states. 6 Regarding proper health resource management driving balanced interventions, the WHO perspective is that "the proper match between the supply of inputs and health system requirements, the balance between capital investments and recurrent costs, and the system's capacity to manage purchased inputs throughout their entire life cycle are vital for the effective delivery of health services and satisfactory performance of the health system." 7 WHO's Integrated Healthcare Technology Package (IHTP) is a planning methodology and softwarebased tool that provides guidance on an adequate mix of resource inputs, including human resources, medical devices, pharmaceuticals and facilities, needed to deliver a defined set of health interventions. IHTP integrates in one single tool the health care needs, disease profiles, patient demographics, clinical practice guidelines (CPGs), resources, availability, costs, constraints, and management capacity. The focus throughout is on prevention and caring for the chronic diseases. 
Examples of CPGs mapped in IHTP for WHO's Integrated Management of Childhood Illnesses (IMCI) program at primary and secondary levels of care include: pneumonia, cold, bronchiolitis, croup, diphtheria, pertussis, tuberculosis, diarrhea, dehydration, dysentery, malnutrition, typhoid fever, meningitis, measles, malaria, dengue fever, otitis media, urinary tract infections, heart failure, hypothermia, HIV/AIDS in children, pneumocystosis, burns, fractures, and head injuries.
This approach also reflects a balance between primary prevention interventions (eg, as demonstrated for hypertension and diabetes) as well as investing in ongoing EBM treatment.
Here are two examples from my colleagues and my own experience with WHO IHTP initiatives in these countries:
Kyrgyzstan (Central Asia):
The initial MOH focus was optimal resource management and care for hypertension in adults, anemia in pregnancy, tuberculosis, acute respiratory illnesses in children, and brucellosis. Later, over 120 CPGs were developed by clinical experts and approved by the MOH at three levels of care. They were then mapped in IHTP, validated, and implemented leading to increased CPG compliance by practitioners.
The following improvements were noted: Resource Planning and Management • Typically "siloed" planning was integrated and databases standardized for the following, resulting in: Human Resources -More family practice staff were identified and trained -Standards set and physician/nurse responsibilities clarified Pharmaceuticals -VAT fees for externally purchased drugs were removed -MOH rules were developed allowing medical drugs sold at sites where local pharmacies are not available -Handling of donated drugs was improved Facilities -Coordination with local governments was improved assuring funding for primary and secondary facility renovations Medical Equipment -National MOH policy was implemented for rational use of medical devices -National MOH policy was implemented for purchase of high technology, high cost devices EBM "ideal" CPGs comparison with current country-level "actual" CPGs using IHTP 
Conclusions
In the difficult challenge of caring for people with chronic diseases such as chronic kidney disease, the most important question is how much should a country invest in caring for the end-stage disease state versus extensive revamping of primary care to enhance preventive interventions? Around the world, my experience is that WHO recommends and assists countries in addressing both imperatives. As you can tell from the work in the two countries I highlighted, the WHO approach is very broad and balanced. I hope you now have a glimpse of how the WHO addresses this very complicated challenge in developing countries. v
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